Table 1.
Pivotal trials and FDA approvals of PARP and VEGF inhibitors in advanced ovarian cancer
| Drug | Maintenance | Later-Line Treatment | FDA Approval |
|---|---|---|---|
| Olapariba | SOLO-2 (BRCA-mutated) Study 19 (Aug 17, 2017) SOLO-1 (BRCA-mutated) (Dec 19, 2018) PAOLA-1 (HRD-positive) (May 8, 2020) |
Study 42 (BRCA-mutated) (Dec 19, 2014) |
> 3rd line, germline BRCA, treatment (Dec 19, 2014) > 2nd line, no biomarker, maintenance after response to platinum (Aug 17, 2017) Front-line, germline and somatic BRCA, maintenance after response to platinum (Dec 19, 2018) Front-line olaparib plus bevacizumab, HRD-positive, maintenance after response to platinum (May 8, 2020) |
| Niraparibb | NOVA (Mar 27, 2017) ENGOT-OV26/PRIMA (April 29, 2020) |
QUADRA (Oct 23, 2019) |
2nd line, no biomarker, maintenance after response to platinum (March 27, 2017) >3rd line, HRD+, germline and somatic BRCA, platinum-sensitive, treatment (Oct 23, 2019) Front-line maintenance after response to platinum (April 29, 2020) |
| Rucaparibc | ARIEL3 (April 6, 2018) |
Study 10 (BRCA-mutated) ARIEL2 (BRCA-mutated) (Dec 19, 2016) |
> 2nd line, germline and somatic BRCA, treatment (Dec 19, 2016) > 2nd line, no biomarker, maintenance after response to platinum (Apr 6, 2018) |
| Bevacizumabd | GOG218 (June 13, 2018) OCEANS – GOG213 (Dec 6, 2016) |
AURELIA (Nov 14, 2014) |
1st and later-line treatment plus maintenance (Nov 14, 2014; Dec 6, 2016; June 13, 2018) |
aOlaparib Prescribing Information. AstraZeneca Pharmaceuticals LP, May 2020; bNiraparib Prescribing Information. Tesaro Inc., April 2020; cRucaparib Prescribing Information. Clovis Oncology Inc., May 2020; dBevacizumab Prescribing Information. Genentech/Roche, May 2020.
FDA: US Food and Drug Administration, HRD: homologous recombination deficiency, PARP: poly ADP ribose polymerase, VEGF: vascular endothelial growth factor.